CeriBell (NASDAQ:CBLL) VP David Foehr Sells 987 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 987 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $17,766.00. Following the completion of the transaction, the vice president directly owned 38,613 shares in the company, valued at $695,034. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, May 22nd, David Foehr sold 862 shares of CeriBell stock. The shares were sold at an average price of $18.80, for a total value of $16,205.60.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The shares were sold at an average price of $17.80, for a total value of $81,168.00.

CeriBell Stock Performance

CBLL stock opened at $18.80 on Wednesday. The stock has a market capitalization of $713.27 million, a PE ratio of -11.53 and a beta of 0.99. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The stock’s 50 day simple moving average is $19.09 and its 200 day simple moving average is $19.24.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The business had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, research analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CBLL. Canaccord Genuity Group lowered their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

Hedge Funds Weigh In On CeriBell

Hedge funds and other institutional investors have recently modified their holdings of the company. CenterBook Partners LP lifted its holdings in shares of CeriBell by 448.0% during the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after buying an additional 389,584 shares during the period. JPMorgan Chase & Co. increased its stake in shares of CeriBell by 8.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock worth $4,724,000 after purchasing an additional 31,177 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of CeriBell in the 3rd quarter worth $158,000. TimesSquare Capital Management LLC increased its stake in shares of CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock worth $9,395,000 after purchasing an additional 20,700 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of CeriBell in the 1st quarter worth $341,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.